The dangers of growing DNA databases
By Osagie K. Obasogie,
Los Angeles Times
| 04. 09. 2010
President Obama may have given credence to a relatively new but questionable law enforcement practice that the rest of the developed world is starting to shun: taking and retaining DNA samples from individuals arrested for a crime but not convicted. That is, putting innocent people's DNA in criminal databases.
During an interview with the president last month on the television program "America's Most Wanted," host John Walsh enthusiastically supported the expansion of this practice in the United States, saying, "We now have 18 states who are taking DNA upon arrest. England has done it for years. It's no different than fingerprinting or a booking photo." To which President Obama said, "It's the right thing to do."
But many in the human rights community disagree. For example, the European Court of Human Rights unanimously ruled in 2008 that the United Kingdom's policy of keeping arrestees' genetic samples after their release -- the very practice that Walsh (and by implication Obama) endorses -- violates a right respecting private and family life codified by the European Convention on Human Rights. At the time...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...